Four names sit in the user's watchlist under Physician Services & Staffing — Agilon Health, AMN Healthcare, Astrana Health and Pediatrix Medical Group — and all four have carried an emerging-bull tag after climbing out of a sustained downtrend that had them all reading strong-bear as recently as mid-2025. That timing matters: AMN, Astrana and Pediatrix confirmed their own uptrends weeks before Agilon's band flipped, so the label is cohort-wide rather than a single-stock artifact riding on Agilon's back. What has changed since is that Agilon's move has since dwarfed the others — up roughly 383% over six months against 30-73% for its three peers — and that divergence is now unwinding two names hard while leaving the other two untouched.

Agilon Health, which contracts to bear full financial risk on Medicare Advantage patients for independent primary-care doctors, fell from $102 to a $9.75 trough in April before rocketing to $91.61 by late July. Medical margin rose to $149M from $128M a year earlier and full-year guidance was lifted to roughly $5.7B in revenue and $375M in medical margin — but membership fell 13.2% year over year, meaning the margin gain came substantially from exiting unprofitable Medicare Advantage contracts rather than organic growth. Citi downgraded the stock to Sell on July 23 even while raising its price target to $105 from $80, citing a 38% valuation premium to peers after a roughly 650% year-to-date run; shares fell about 11% that day and have since given back roughly a quarter of their value. A separate overhang, a stockholder investigation into potential misstatements about Agilon's medical costs, adds to the case that the tape has run ahead of the story.

AMN Healthcare, the largest US healthcare staffing firm for travel nurses and physician locums, reported Q1 revenue that roughly doubled year over year, but nearly $722M of that was one-off nurse labor-disruption revenue management itself called unsustainable, with Q2 guidance of $620-635M implying a steep sequential drop. Core locums revenue fell 6% year over year on lower days filled, and industry-wide travel-nurse revenue is edging up only about 1% in 2026 with bill rates still pressured — a plateau, not an inflection. Yet AMN trades with no meaningful trailing P/E and a price-to-sales ratio near 0.37x, and its stock was flat over the past month while Agilon and Astrana sold off.

Astrana Health, which runs capitated, full-risk physician networks, posted 55.6% revenue growth substantially fueled by its Prospect Health acquisition rather than organic capitation growth alone. After an 86.5% year-to-date run, commentary flagged the stock as fully valued at roughly 73x trailing earnings, and its mid-July pullback was tied to broad sector rotation rather than any Astrana-specific news; shares are down 28.6% over the trailing month.

Pediatrix Medical Group, which staffs neonatal, maternal-fetal and pediatric subspecialty physicians nationally, is the steadiest of the four: trailing earnings near 12.9x, and management reaffirmed $280-300M adjusted EBITDA guidance with stable payor mix, explicitly noting it hasn't seen the unfavorable mix shifts reported elsewhere in the sector. The whole cohort also gets a shared macro tailwind: CMS's final CY2027 Medicare Advantage rate notice raised the net payment increase to 2.48% (4.98% including risk-score trend), well above the 0.09% initially proposed, supporting risk-bearing providers broadly into next year. Pediatrix reports Q2 results August 4, with Agilon following August 5 — the nearest live test of which fundamental story the shared label actually reflects.

The setup

Where it stands — Cohort tag is real and predates AGL's move, but the recent pullback is concentrated in AGL and ASTH while AMN and MD held flat. Would confirm — AMN core locums revenue stabilizes or turns positive and AGL membership stops shrinking in the Q3 print. Would invalidate — Agilon or Astrana resume new highs on no fresh operating data, widening the valuation gap further. Watch next — Pediatrix reports August 4, 2026; Agilon reports August 5, 2026. Valuation — MD ~12.9x trailing earnings; ASTH ~73x trailing; AMN and AGL have no meaningful trailing P/E versus roughly 0.36-0.37x price-to-sales each.